Translator Disclaimer
5 March 1993 Photodynamic therapy in two murine tumor models with sulfonated aluminum phthalocyanine
Author Affiliations +
Proceedings Volume 1616, International Conference on Photodynamic Therapy and Laser Medicine; (1993) https://doi.org/10.1117/12.137032
Event: International Conference on Photodynamic Therapy and Laser Medicine, 1991, Beijing, China
Abstract
Photodynamic therapy (PDT) with sulfonated aluminum phthalocyanine (AlSPC), i.e., AlSPC-PDT, in two murine tumor models is reported here. The encouraging therapy results were observed in S180 fibrosarcoma transplanted in white mice of the Kunming line and in human hepatocellular carcinoma transplanted in balb/c nu/nu nude mice. The experimental tumors in the mice were chosen of those 0.5 - 0.8 cm in diameter and 0.4 - 0.7 cm in thickness. Photofrin II (PII) and Photosensitizing drug-007 (PSD-007), two kinds of porphyrin derivative dyes, were chosen as the contrast photosensitizers of AlSPC. A dose of 10 mg/kg AlSPC or PII or PSD-007 was given (iv). The dose of light (600 - 750 nm) was 180 J/cm2. `Cure (short-term)' was defined as regression of neoplastic tissue to a non-palpable tumor within 14 days after PDT. `Cure (long-term)' was defined as absence of local tumor tissue and tumor metastasis on gross and microscopic examinations within 107 days after PDT. The curative results suggest that AlSPC may be a more effective sensitizer than both PII and PSD-007.
© (1993) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Hong-Yu Yu, Rong-Chun Dong, Ji-Yao Chen, and Huai-Xin Cai "Photodynamic therapy in two murine tumor models with sulfonated aluminum phthalocyanine", Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993); https://doi.org/10.1117/12.137032
PROCEEDINGS
7 PAGES


SHARE
Advertisement
Advertisement
Back to Top